EGRIFTA SV Drug Profile

Summary for Tradename: EGRIFTA SV

High Confidence Patents:	9
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for EGRIFTA SV

See drug prices for EGRIFTA SV

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for EGRIFTA SV Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for EGRIFTA SV Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Theratechnologies Inc.	EGRIFTA SV	tesamorelin	For Injection	022505	5,861,379		DrugPatentWatch analysis and company disclosures
Theratechnologies Inc.	EGRIFTA SV	tesamorelin	For Injection	022505	6,020,311		DrugPatentWatch analysis and company disclosures
Theratechnologies Inc.	EGRIFTA SV	tesamorelin	For Injection	022505	7,144,577		DrugPatentWatch analysis and company disclosures
Theratechnologies Inc.	EGRIFTA SV	tesamorelin	For Injection	022505	7,316,997		DrugPatentWatch analysis and company disclosures
Theratechnologies Inc.	EGRIFTA SV	tesamorelin	For Injection	022505	8,314,066		DrugPatentWatch analysis and company disclosures
Theratechnologies Inc.	EGRIFTA SV	tesamorelin	For Injection	022505	8,435,945		DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for EGRIFTA SV Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Theratechnologies Inc.	EGRIFTA SV	tesamorelin	For Injection	022505	10,668,053	2034-05-02	Patent claims search
Theratechnologies Inc.	EGRIFTA SV	tesamorelin	For Injection	022505	8,980,249	2031-06-03	Patent claims search

International Patents for EGRIFTA SV

Country	Patent Number	Estimated Expiration
Brazil	122020023215
South Korea	20160003212
Mexico	2015015230
China	110694077
Mexico	2021001878
Spain	2842206

Market Dynamics and Financial Trajectory of EGRIFTA SV

Last updated: April 20, 2026

What is EGRIFTA SV?

EGRIFTA SV (tesamorelin) is a peptide-based biologic developed by Theratechnologies. Approved by the U.S. Food and Drug Administration (FDA) in 2021, it is indicated for the reduction of excess visceral adipose tissue (VAT) in HIV-infected patients with lipodystrophy. The drug functions as a growth hormone-releasing factor (GHRF) analog, stimulating the pituitary gland to increase endogenous growth hormone (GH) secretion.

Market Size and Segment Analysis

Currently Approved Indications and Market Scope

EGRIFTA SV addresses a niche within the HIV-associated lipodystrophy space, with an estimated affected population of about 400,000 patients in the U.S., according to industry reports [1]. Remaining markets for the drug include Canada and select European countries, subject to regulatory approval.

Revenue Estimates and Growth Drivers

Projected U.S. sales for EGRIFTA SV hover between $150 million and $200 million within the next five years, driven by:

• Increasing awareness among physicians
• Stable prevalence of HIV globally (around 38 million people, per UNAIDS [2])
• Limited competition in the niche biologic segment

Competitive Landscape

The market faces minimal direct competition:

• Current treatment options focus on lifestyle modifications and off-label interventions.
• No biosimilar or generic versions are available as of 2023.
• Biological treatments for lipodystrophy are scarce; tesamorelin’s unique mechanism offers a competitive edge.

Market Dynamics Influencing Adoption

Regulatory Factors

Regulatory approval in other regions remains a key determinant. EGRIFTA SV's FDA approval establishes a benchmark, but European Medicines Agency (EMA) approval depends on local dossier submissions and comparability assessments, which may slow broader adoption.

Patient and Physician Acceptance

Physician familiarity and comfort with growth hormone-related therapies influence prescribing patterns. The potential for adverse effects such as edema, arthralgia, or glucose intolerance may limit long-term use.

Reimbursement and Pricing Strategies

Pricing strategies will influence market penetration:

• In the U.S., list prices are approximately $250 per dose.
• Insurance coverage and prior authorization requirements impact patient access.
• Cost-effectiveness analyses favoring EGRIFTA SV over off-label treatments can expand market share.

Healthcare Market Trends

The shift toward personalized medicine and biologics favors higher adoption rates for EGRIFTA SV. The HIV care landscape emphasizes managing lipodystrophy symptoms to improve quality of life.

Financial Trajectory and Investment Outlook

Revenue Forecasts

• Year 1 (2023–2024): Launch phase, ~$50 million in U.S. revenue.
• Year 3 (2025–2026): Expansion phase, estimates range between $100 million and $150 million.
• Year 5 (2027): Potential peak revenues between $150 million and $200 million, contingent on market uptake and additional regional approvals.

Cost Considerations

Manufacturing costs for biologics remain high, with estimates around 40-50% of ex-factory price due to complex production processes. Marketing and sales expenses are projected to account for 20-25% of revenue, primarily for physician education and patient outreach.

Risks and Challenges

• Competition from emerging therapies targeting lipodystrophy.
• Potential safety concerns may hamper long-term prescribing.
• Regulatory delays in key markets could hinder expansion.

Key Takeaways

• EGRIFTA SV targets a niche market, with a stable but limited patient population.
• Revenue is expected to grow steadily over five years, reaching up to $200 million annually in the U.S.
• Market uptake is driven by regulatory approval, physician familiarity, and reimbursement policies.
• The biologic’s limited competition presents a favorable landscape but requires ongoing safety and efficacy monitoring.
• Expansion to international markets remains a critical growth opportunity.

FAQs

1. What are the main therapeutic advantages of EGRIFTA SV?
It addresses visceral fat reduction in HIV-associated lipodystrophy with a targeted, biologic approach, offering a specific treatment option where few alternatives exist.

2. How does the drug’s pricing impact market penetration?
Pricing at approximately $250 per dose may limit access for some patients, but insurance reimbursement and cost-effectiveness will influence uptake.

3. Are there safety concerns associated with EGRIFTA SV?
Common adverse effects include swelling, joint pain, and blood sugar abnormalities. Long-term safety data are still emerging.

4. Which regions are likely to see regulatory approval next?
Europe and Canada are primary candidates, with approval pending the submission of dossiers and regulatory review processes.

5. How does EGRIFTA SV compare to other biologics for lipodystrophy?
It remains unique in its indication and mechanism but faces competition from potential future therapies targeting lipodystrophy directly or indirectly.

---

References

[1] Industry Reports. (2023). Market Analysis of HIV-Related Lipodystrophy Therapeutics.

[2] UNAIDS. (2022). Global HIV & AIDS Statistics—2022 Fact Sheet.

[3] U.S. Food and Drug Administration. (2021). EGRIFTA SV Approval Document.